Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)
ID: 358886Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358886
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Trailblazer Award aimed at New and Early-Stage Investigators, with a focus on integrating engineering and physical sciences with life and biomedical sciences. This grant opportunity, utilizing the R21 activity code, encourages innovative research projects that may be exploratory, developmental, or high-risk high-impact, and aims to foster collaborations that open new areas of biomedical investigation. Interested applicants, particularly those with expertise in engineering and quantitative sciences, should prepare to submit their applications once the NOFO is officially released, with an estimated synopsis post date of November 21, 2025, and a projected award date of October 1, 2026. For further inquiries, potential applicants can contact Randy King at the National Institute of Biomedical Imaging and Bioengineering via email at Randy.King@nih.gov or by phone at 301-451-0707.

    Point(s) of Contact
    Randy King National Institute of Biomedical Imaging and Bioengineering (NIBIB)
    (301) 451-0707
    Randy.King@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators, a federal grant aimed at fostering innovative biomedical research that integrates engineering with life sciences. This funding opportunity, under the R21 Exploratory/Developmental Research Grant mechanism, allows for up to $400,000 in direct costs over a three-year period for projects that require minimal preliminary data, encouraging high-risk, high-reward research. The initiative is designed to enhance diversity within the research community and is open to a wide range of eligible applicants, including various educational institutions and community organizations. Interested parties should note that the application submission period opens on January 16, 2025, and closes on January 8, 2026; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators through the R21 Clinical Trial Optional grant mechanism, aimed at fostering innovative research that integrates engineering and physical sciences with biomedical sciences. This funding opportunity encourages exploratory, proof of concept, or high-risk projects, specifically those that do not require extensive preliminary data, allowing applicants to propose novel research approaches. Eligible applicants include a diverse range of institutions and organizations, with funding of up to $400,000 available over a maximum of three years. Interested parties should submit their applications electronically via Grants.gov by the close date of January 7, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Small Business Transition Grant aimed at early-career scientists, specifically under the R41/R42 activity code, with a focus on supporting their transition to entrepreneurship. This initiative seeks to address the challenges of identifying the right expertise and securing funding for early-stage technology development, thereby facilitating the transfer of innovative technologies from academic laboratories to small businesses. The program is crucial for fostering technological innovation in the U.S. and is expected to award approximately 20 grants, with applications anticipated to open in Fall 2025. For further inquiries, interested parties can contact Dr. Saroj Regmi at saroj.regmi@nih.gov or call 240-276-7289.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a Notice of Funding Opportunity (NOFO) for the National Centers for Biomedical Imaging and Bioengineering (NCBIB), with a focus on advancing research in biomedical imaging and bioengineering. This grant opportunity, identified as P41 Clinical Trials Optional, aims to foster meaningful collaborations and innovative projects within the research community. The anticipated funding amount for this initiative is up to $750,000, with the NOFO expected to be published in late summer 2023 and applications due in fall 2023. Interested applicants should prepare for the estimated project start date of July 30, 2024, and can expect the award announcement by June 30, 2024.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) under the R01 Clinical Trial Optional program, aimed at fostering collaborations between life and physical sciences to address biomedical challenges. The grants encourage multidisciplinary bioengineering approaches that integrate and accelerate the adoption of innovative tools and methods for research or clinical problems in basic, translational, or clinical science. This funding opportunity is particularly significant for small teams looking to enhance understanding and solve issues in biological and clinical sciences. Interested applicants can reach out to Dr. Miguel R. Ossandon at ossandom@mail.nih.gov or by phone at 240-276-5714, with an estimated award date of December 1, 2026, and a closing date for applications on February 5, 2026. The program anticipates awarding approximately 50 grants, with no cost-sharing or matching requirements.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.